EMA recommends approval of Vintafolide [Vynfinit] as a new treatment for platinum-resistant ovarian cancer together with companion diagnostic.
March 21, 2014 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Vynfinit (vintafolide) for the treatment of women with a subtype of platinum-resistant ovarian cancer for which there …